Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
NCT ID: NCT01487278
Last Updated: 2014-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal
NCT01713153
Misoprostol for the Treatment of Postpartum Hemorrhage
NCT00116350
Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities
NCT01710566
Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan
NCT00120237
Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
NCT01863706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Misoprostol
600 mcg oral misoprostol administered during the third stage of labor
misprostol
600 mcg misoprostol oral
UnijectTM
10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
UnijectTM
10 IU oxytocin delivered intramuscularly with UnijectTM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
misprostol
600 mcg misoprostol oral
UnijectTM
10 IU oxytocin delivered intramuscularly with UnijectTM
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Aga Khan Foundation
OTHER
Guttmacher Institute
OTHER
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayisha R Diop, MPH
Role: PRINCIPAL_INVESTIGATOR
Gynuity Health Projects
Laura J Frye, MPH
Role: PRINCIPAL_INVESTIGATOR
Gynuity Health Projects
Yacouba Kone, M.D
Role: PRINCIPAL_INVESTIGATOR
The Aga Khan Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Villages in Mopti
Mopti, , Mali
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2.4.8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.